Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results

With Novo Nordisk’s GLP-1 drug Ozempic (semaglutide) on its tail, Eli Lilly has rounded up some mid-stage data to show it has the right candidate to follow on Trulicity’s blockbuster success in the competitive diabetes market.